ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Director Dumps $410M in NVIDIA as Mystery Buyer Snaps Up $716M of Evolution

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

An NVIDIA director filed to disclose more than $410M in open-market sales in early September, while a secretive billionaire revealed a $716M buying spree in Swedish gaming group Evolution.

Mark Stevens, an independent director at NVIDIA, filed on 2 September showing he sold 1.35 million shares across two days at prices ranging from $220 to $226. Total proceeds came to roughly $410M. The filings cover trades on 31 August and 2 September. NVIDIA shares have rallied sharply over the past year, which makes the timing unsurprising, but the scale is notable for a single board member.

The bigger story sits in Stockholm. Kenneth Bryan Dart, the reclusive Cayman Islands-based billionaire who rarely surfaces in filing data, disclosed on 26 August that he bought 10 million Evolution shares in late July for a combined $716M. His stake now stands at around 30% of the company. The purchases were at SEK 689 to 695 per share. No activist intent has been stated, but a buyer quietly accumulating 30% of a listed company is rarely a passive signal.

Gland Pharma saw its promoter-group shareholder Fosun Pharma Industrial sell roughly $296M in shares in early September, filed 8 September. That continues a pattern of Fosun reducing its Indian pharmaceutical exposure.

The vendor data used here covers non-US markets directly; US trades are sourced from SEC filings. The most recent data available runs to early September 2026.

Stocks in this article

How this article was generated

Generated
2 Nov 2026, 00:12
Prompt version
v1.0
Data sources
Institutional positioningAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.